 |
 |

Evaluation of Excessive Anticoagulation in a Group Model Health Maintenance Organization
Tammy R. Lousberg, PharmD;
Daniel M. Witt, PharmD;
Donna G. Beall, PharmD;
Barry L. Carter, PharmD;
Daniel C. Malone, PhD
Arch Intern Med. 1998;158:528-534.
Background The fourth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy recently published guidelines that included recommendations regarding the management of excessive anticoagulation. Limited data are available to support these recommendations.
Objectives To assess management and outcomes of excessive anticoagulation in a group model health maintenance organization, compare management with the published guidelines, and analyze the cost of treatment strategies.
Methods A search of computerized laboratory information identified patients with an international normalized ratio (INR) of greater than 6.0 during the 9-month study. Pertinent data were collected through a retrospective medical record review. Information was concurrently collected for cost analyses.
Results The analysis included 301 episodes of excessive anticoagulation among 248 patients. Most (83%) episodes of elevated INRs were managed conservatively by a temporary discontinuation of warfarin sodium therapy until the INR was in a therapeutic range. Conservative management resulted in no sequelae in 212 (85.1%) of 249 episodes. Two episodes (0.8%) of major bleeding evolved in patients managed conservatively. No sequelae were documented in 23 (44%) of 52 episodes of phytonadione (vitamin K1) administration. Sixteen (31%) episodes of major bleeding were documented, but bleeding occurred before phytonadione administration in all cases. Administering phytonadione resulted in hospital admission for 3 patients2 (3.8%) because of thromboembolism and 1 (1.9%) for the administration of heparin sodium. Cost-effectiveness analysis determined that treatment with phytonadione is 7 times more costly than conservative management when INRs are between 6.0 and 10.0.
Conclusions Most episodes of excessive anticoagulation were not managed per consensus guidelines. The higher the INR, the more likely were interventions to adhere to the guidelines. Administering phytonadione to patients with a moderate elevation of INRs (6.0-10.0) may be unnecessary. Based on this study, conservative management is a viable option.
From the Clinical Pharmacy Services, Department of Pharmacy, Kaiser Permanente, Rocky Mountain Division, Boulder (Dr Lousberg), Westminister (Dr Witt), and Aurora (Dr Beall), Colo; and the Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver (Drs Lousberg, Witt, Beall, Carter, and Malone).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin: A Randomized Trial
Crowther et al.
ANN INTERN MED 2009;150:293-300.
ABSTRACT
| FULL TEXT
Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT
| FULL TEXT
Management of Excessive Anticoagulant Effect Due to Vitamin K Antagonists
Dentali and Crowther
ASH Education Book 2008;2008:266-270.
ABSTRACT
| FULL TEXT
The Risk of Hemorrhage Among Patients With Warfarin-Associated Coagulopathy
Garcia et al.
J Am Coll Cardiol 2006;47:804-808.
ABSTRACT
| FULL TEXT
Warfarin reversal
Hanley
J. Clin. Pathol. 2004;57:1132-1139.
ABSTRACT
| FULL TEXT
The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Ansell et al.
Chest 2004;126:204S-233S.
ABSTRACT
| FULL TEXT
Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review
Wilson et al.
CMAJ 2004;170:821-824.
ABSTRACT
| FULL TEXT
A Survey of Oral Vitamin K Use by Anticoagulation Clinics
Libby and Garcia
Arch Intern Med 2002;162:1893-1896.
ABSTRACT
| FULL TEXT
Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy: A Randomized, Controlled Trial
Crowther et al.
ANN INTERN MED 2002;137:251-254.
ABSTRACT
| FULL TEXT
Treatment of Warfarin-Associated Coagulopathy : A Physician Survey
Wilson et al.
Chest 2001;120:1972-1976.
ABSTRACT
| FULL TEXT
Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin
Hylek et al.
ANN INTERN MED 2001;135:393-400.
ABSTRACT
| FULL TEXT
Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation
Gage et al.
ANN INTERN MED 2001;134:465-474.
ABSTRACT
| FULL TEXT
Anticoagulation Therapy
Ginsberg et al.
ASH Education Book 2001;2001:339-357.
ABSTRACT
| FULL TEXT
Managing Oral Anticoagulant Therapy
Ansell et al.
Chest 2001;119
:22S-38S.
FULL TEXT
Prospective Study of the Outcomes of Ambulatory Patients With Excessive Warfarin Anticoagulation
Hylek et al.
Arch Intern Med 2000;160:1612-1617.
ABSTRACT
| FULL TEXT
|